Trial Profile
An Open-Label, Randomized, 2-Period Crossover Study to Demonstrate the Definitive Bioequivalence of a Single Dose of a Tablet Form of MK0974 Ethanolate Vs. a Single Dose of the Reference MK0974 Liquid Filled Capsule in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Telcagepant (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 01 Sep 2009 New trial record